Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:21:23.377Z.
Calculation as of: 2026-10-06T14:21:23.377Z.
Quote observation: 2026-10-06T14:19:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 07daf27a5d98c2e6040b1a84eec716383e035dd1d7ed5c9da608703ba97b77ea
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$31.23M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$27.60M
Price/FCF Ratio
N/A
TTM Avg
87.13
3Y Avg
87.13
5Y Avg
45.44
Market Cap
$31.62M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CervoMed Inc. (CRVO) | $29.57M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.10M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $28.35M | N/A | N/A | N/A | N/A |
| MDxHealth S.A. (MDXH)vs › | $31.10M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.23M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.60M | N/A | 87.13 | 87.13 | 45.44 |
| BeyondSpring Inc. (BYSI)vs › | $31.45M | N/A | N/A | N/A | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $31.62M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $31.80M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $33.24M | N/A | 507.99 | 507.99 | 507.99 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
